To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Alpha-PET for Prostate Ca… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Alpha-PET for Prostate Cancer: Preclinical investigation using Tb-149-PSMA-617

Journal article
Authors C. A. Umbricht
U. Koster
Peter Bernhardt
N. Gracheva
K. Johnston
R. Schibli
N. P. van der Meulen
C. Muller
Published in Scientific Reports
Volume 9
Pages 10
ISSN 2045-2322
Publication year 2019
Published at Institute of Clinical Sciences, Department of Radiation Physics
Pages 10
Language en
Keywords radionuclide therapy, radioligand therapy, membrane antigen, in-vivo, dosimetry estimate, long-term, inhibitors, Science & Technology - Other Topics
Subject categories Biomedical Laboratory Science/Technology


In this study, it was aimed to investigate Tb-149-PSMA-617 for targeted a-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Tb-149-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. Tb-149-PSMA-617 was applied at 1 x 6 MBq (Day 0) or 2 x 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 x 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the beta(+)-emission of Tb-149, tumor localization was feasible using PET/CT after injection of Tb-149-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of Tb-149-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of Tb-149 for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand's tissue distribution.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?